Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025

ARROWHEAD PHARMACEUTICALS, INC.

2025-Q2 EPS reported $1.52 vs consensus -$1.05 ▲ beat (+245.4%)

Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).
GAAP diluted EPS $2.75 vs ($1.02) loss YoY; net income $370.4M.
FDA accepted plozasiran NDA for FCS with PDUFA date Nov 18, 2025; no advisory committee planned.
CFO Ken Myszkowski retiring May 13, 2025; succeeded by Daniel Apel.
Cash and investments $1.097B; company funded into 2028 with no near-term equity needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.